• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Syngene

    Aphena Pharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Alcami

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    API Sourcing

    What factors dictate the migration to China?

    Related CONTENT
    • Hovione
    • India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    • Frontida BioPharm Launches Expansion Efforts
    • Recro Gainesville Expands Mfg. Capabilities
    • Diverse Products And Technologies Delivered
    Ed Silverman01.22.10
    Three years ago, AstraZeneca was embarrassed when its plans for sourcing active pharmaceutical ingredients from China were accidentally disclosed. The drug maker engaged in a fit of furious backpedaling as it tried to downplay remarks by some of its own executives that production in such places as the UK and Germany would eventually be phased out in favor of lower-cost China.

    Why was the drug maker so keen to deny that China represented the future of API sourcing? For those who can't recall, the headlines at the time conveyed alarming stories about unadulterated medicines, poisoned dog food and toxic toys stemming from China. Not exactly a good time to announce plans to source key pharmaceutical ingredients from a country that was likened to the Wild West (even if it is in the Far East).

    This gaffe, moreover, occurred a few months before the notorious Heparin scandal in which several deaths were linked to a tainted substance found in the widely used injectable blood-thinning medication sold by Baxter. That episode prompted Congressional inquiries into the FDA and its ability to monitor the flow of products coming from China which, of course, includes facilities inspections.

    Why are we dredging up these stories now? We were reminded of these events when AstraZeneca recently acknowledged long-sought efforts to build up its manufacturing presence in China, which includes a big factory in Wuxi where, in addition to making APIs, medicine formulation and packaging also are conducted. But AstraZeneca isn't the real story here; the drug maker merely symbolizes a trend that isn't going away - ever.

    As drug makers work harder every day to wring costs out of their mammoth structures, China is taking on more importance all the time. And this effect is, of course, multiplied by the potential of the large domestic Chinese market that drug makers want to tap as a much-needed source of additional revenue. The Chinese pharmaceutical market, in fact, grew 24% in the 12 months ended June 2009, according to IMS Health.

    Whatever the ultimate product destination, though, more manufacturing will be done in Asia, especially China, according to a 2008 report by PricewaterhouseCoopers report. When considering such parameters as cost, risk and market opportunity, China scored as the best outsourcing destination, in general. And the lower costs and greater market opportunity for both China and India outweighed more established and mature countries such as Australia, Singapore and Japan.

    This begs one overarching question: is all this outsourcing to China a good idea whose time has not yet come? Money will, of course, dictate what happens in the marketplace. And lower costs are, well, lower costs. For instance, if one compares the per-kilo price, but ignores standards for Good Manufacturing Practices and Health, Safety and Environment, the difference in APIs from China or the West could be two to five times, according to Guy Villax, chief executive officer of Hovione, an API manufacturer based in Lisbon, Portugal. On the other hand, sourcing from equivalent suppliers, and factoring in GMP and HSE, and having some assurance of continuity of supply, the difference in price is more likely to be expressed in percentage terms. And so, arguing with the economics is difficult.

    But this is more than an economics lesson, of course. Repeated scandals can be difficult memories to erase from the public consciousness. Just like Vioxx has become a buzzword in discussions about safety and marketing, Heparin has arguably become synonymous with poor quality and poor oversight.

    Indeed, impressions are made worse when the FDA is vilified for failing to work harder at preventing some of these widely publicized episodes. There may be a new, consumer-conscious regime at the top of the agency now, but it's not clear that much, if anything, will change anytime soon, despite pronouncements by FDA commissioner Margaret Hamburg to improve product safety across the board.

    An FDA spokeswoman says that there are just two agency inspectors on the ground in China for scrutinizing medical products, although "many" inspectors based in the U.S. make short-term trips to China to conduct inspections. How much is accomplished on such trips isn't clear, unfortunately. And there was no further information about the number of trips or how many inspectors travel to China to compensate for the lack of personnel stationed in the country. And the agency spokeswoman added that, for now, there are no plans to add more inspectors there. In other words, the FDA's ability to detect serious problems doesn't appear to have changed appreciably.

    Meanwhile, along with India, China reportedly supplies about 40% of the APIs used to make pharmaceuticals that are sold in the U.S. Repeated scandals have prompted Chinese authorities to tighten laws, but enforcement remains weak and transparency is minimal, according to a recent report from the American Enterprise Institute. That said, the move three years ago to execute Zheng Xiaoyu, the former director of China's State Food and Drug Administration, for approving untested medicine in exchange for cash from eight drug and medical equipment companies, left quite an impression.

    Publicity over lethal injections aside, the vapid state of Chinese regulation poses a dilemma for drug makers, which already suffer from some of the worst corporate bashing over the past decade, thanks to their own safety scandals and ongoing pricing debates. One needn't be Machiavelli to understand that poor quality control, unscrupulous suppliers or lax oversight can lead to irreparable trouble - and not just in terms of public image, but in actual sales. Imagine the fallout that would occur if the Heparin scandal were to be repeated at another couple of drug makers in a relatively short period of time.

    But trying to stay on the straight and narrow can prove daunting. And that's no secret, is it? This is especially true in China, a vast country where regulatory norms are obviously still evolving and will, in all likelihood, take still more time to match Western standards. This means, however, that drug makers must work overtime, so to speak, to ensure their suppliers - or their own employees - are well-versed in the sort of regulatory procedures that customers in the West have come to demand.

    Toward that end, drug makers are increasingly grappling with checking supplier management systems and conducting supplier audits as a means of ensuring supply-chain security. And several drug makers are reportedly working with the Pharmaceutical Research and Manufacturers Association to bring nearly two dozen inspectors from China's SFDA to the U.S. for several weeks to provide them with a better understanding of GMPs. Such efforts are bound to yield some positive results, although this is unlikely to happen overnight.

    "The Chinese infrastructure and organization can be good, but the downside is knowledge of regulations is not particularly wide," said Martin Slade of UK-based outsourcing specialist at GMP Associates and who is also a consultant to Pharmaceutical Development Services. "Anybody from the West would have to have somebody fluent in Chinese and technical language. But it's regulatory issues, too, not just chemistry.

    "One needs to build relationships with suppliers. It's almost paramount in China. The problem, however, is that a lot of API companies in China have some way to go to meet modern requirements. They're not daft, though. Most have certainly caught on fast and, increasingly, it seems to me there are more quality manufacturers offering products for marketing in the West."

    Maybe so. But not surprisingly, the sweeping shift toward China is prompting an outcry. A recent editorial in PharmaBiz, a web site that tracks India's pharmaceutical industry, bemoaned the poor quality of APIs emanating recently from China, which displaced much of India's homegrown API industry during the past decade. "There is a steady rise in the import of substandard and spurious APIs" since 2003, according to the December commentary, which noted how several recent shipments were seized by inspectors.

    Recently, a heated row recently broke out in Europe, where an industry trade group, the Active Pharmaceuticals Ingredients Committee, wants the European Commission to require repeated, mandatory inspections of overseas API facilities, particularly those in . . . drum roll, please . . . China. Of course, a key motivation for the demand is competition - European API suppliers need to preserve business. But given the concerns about Chinese APIs, the APIC can win kudos by coming down on the side of safer products.

    The APIC was prompted to act after the European Commission excluded overseas mandatory inspections from a recent draft directive, saying these reviews would be too expensive, an explanation the APIC called absurd. European suppliers, of course, believe mandatory inspections are needed to keep falsified products out of the EU. And meanwhile, the Committee on Industry, Research and Energy, ITRE, believes that 40 inspectors at the EU level would be needed for the inspection programs.

    These groups have a good point. Consider that European inspectors visited non-Western drug factories just 19 times in 2008, a number that doesn't offer much confidence. And while it's not clear how many inspections were made by FDA staff or the number of facilities they visited in a recent year, the combined effort by presumably experienced U.S. and European inspectors is a pittance compared to the potential for trouble.

    But if regulators lack the mandate, the funds or the will to do more, where are we left? The situation may not be quite as bleak as the numbers and criticisms suggest, at least not across the board, according to one wag. That's because it's worth making distinctions between what companies when it comes to manufacturing the newest and biggest-selling medications compared with other drugs, such as generics or older medicines that will soon face lower-cost generic competition.

    After all, there is considerably less investment - both financial and emotional - that will be made by a company to maintain a product name that is no longer of marquee value. The same goes for a company that is merely introducing a cheap generic. In other words, a new or hot-selling drug with a valuable brand name is likely to cause a company to be more cautious about where it obtains its APIs, or so the theory goes.

    "There are many APIs that come from China today - about 37,000 tons of paracetamol active ingredient, for instance, leave the PRC for the U.S. every year, but probably not a single API for a recently approved drug," said Mr. Villax, the chief executive officer at Hovione, which is a member of the APIC.

    "The newer the drug, the more profitable it is, and so the less risk that the innovator will want to take and the more likely that the later phases of the drug- packing, formulation, API, registered steps - are done in the West, maybe not even outsourced. At the other extreme of the life cycle, chances are a growing amount of generics are formulated in Asia, especially India, and the APIs are coming from China," he continued.

    "Today, large pharma is sourcing APIs from China for large volume, low-margin, off-patented compounds, but they invest heavily in sourcing and auditing, and they usually will use a handful of producers, and chances are that most large firms use the same small number of producers."

    Going forward, it would appear unlikely, for now anyway, that big pharma companies will build their own API facilities for small molecules in places such as China, he added. Rather big drug makers will find ways to work together, if need be, to ensure the quality of their supply chains. But it's clear that the rate at which sourcing APIs from China is taking place is not going to slow down.

    Ed Silverman is a prize-winning journalist who has covered the pharmaceutical industry for The Star-Ledger of New Jersey, one of the nation's largest daily newspapers, for more than 12 years. During that time, he has closely followed a variety of topics of concern to those who work for, and with, pharmaceutical manufacturers - drug development, mergers and acquisitions, regulatory oversight, safety and pricing controversies, and marketing issues. Prior to joining The Star-Ledger, Ed spent six years at New York Newsday and previously worked at Investor's Business Daily. Ed blogs about the drug industry at Pharmalot.
    Related Searches
    • contractpharma.com
    • GMP
    • Outsourcing
    • Pharma
    Suggested For You
    Hovione Hovione
    India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    In vivo Models Targeting Respiratory Diseases In vivo Models Targeting Respiratory Diseases
    Heptares Gets $12mn AstraZeneca Milestone Heptares Gets $12mn AstraZeneca Milestone
    AstraZeneca, Heptares in Immuno-oncology Pact AstraZeneca, Heptares in Immuno-oncology Pact
    Sanofi, MedImmune in RSV Alliance Sanofi, MedImmune in RSV Alliance
    Financial Report: Lilly Financial Report: Lilly
    Hovione, Vertex in Continuous Mfg. Pact Hovione, Vertex in Continuous Mfg. Pact
    Hovione Acquires Formulation Plant Hovione Acquires Formulation Plant
    Hovione Appoints Sales and Marketing VP Hovione Appoints Sales and Marketing VP

    Related Pharma Beat

    • Drug Development

      NSAIDs – Friend or Foe?

      Although widely used for years, NSAIDs have side effects that could eventually change their OTC status
      Adele Graham-King, Contributing Editor 06.06.17

    • Drug Development | Drug Discovery
      Tackling TB Resistance

      Tackling TB Resistance

      The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani
      Adele Graham-King, Contributing Editor 05.09.17

    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17


    • Drug Delivery | Drug Development | R&D

      ‘Smart’ Heparin Delivery Could Self-Modulate

      A group of researchers have spent the past two years investigating self-controlling dosing and monitoring systems
      Adele Graham-King, Contributing Editor 01.26.17

    • Drug Development | Drug Discovery | R&D

      Is Nicotine Such a ‘Bad Boy’?

      Investigating this controversial compound’s potential health benefits
      Adele Graham-King, Contributing Editor 11.09.16

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16


    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16

    • Drug Development

      Chipping Away at the Old Cancer Block

      Advances in cancer treatment continue to march towards finding a cure
      Adele Graham-King, Contributing Editor 04.05.16

    • Clinical Trials | Drug Development

      The 3D Printed Pill

      It’s the future…or is it?
      Adele Graham-King, Contributing Editor 01.28.16


    • Clinical Trials | Drug Development | Drug Discovery | R&D

      Are We There Yet?

      Many promising cancer treatments are on the horizon
      Adele Graham-King, Contributing Editor 07.14.15

    • APIs | Bioassay Development | Drug Development | Methods Development | Process Development | Toxicology

      The Last Chance Saloon?

      Looking at the pharmaceutical ‘diet’ of anti-obesity drugs
      Adele Graham-King, Contributing Editor 06.02.15

    • Clinical Trials | Drug Development

      100 New Drugs in 10 Years?

      Repurposing drug candidates that never saw the light of day
      Adele Graham-King, Contributing Editor 03.06.15


    • APIs | Bioassay Development | Clinical Trials | Drug Development | Drug Discovery | Methods Development | Process Development | R&D | Toxicology

      Experimental Drugs

      To use or not to use unlicensed drugs? That is the question.
      Adele Graham-King, Contributing Editor 01.29.15

    • Drug Delivery | Drug Development
      The End of a Century

      The End of a Century

      Looking at 15 years of pharmaceutical evolution.
      Adele Graham-King 10.14.14

    • Chemistry | Drug Discovery | Supply Chain

      Toward a Process-Centered Pharma

      Saying “No” to change is normal, but adopting true QbD practices could save the industry about 20-25% of its global revenue and allow pharma to add two to three billion patients to its customer base
      Girish Malhotra, EPCOT International 06.03.14

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ingredient Manufacturers Discuss the E-Sports Market
    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Eitan Medical Receives FDA Clearance for Sapphire Infusion System
    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Flow Launches Collagen Waters
    Associations Congratulate Biden & Harris
    David Stanko Joins JPMS
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login